Mymetics to work with French major on flu vaccine

US biotech firm Mymetics Corp (OTCQB: MYMX) says its European subsidiary has entered into a research agreement to investigate the immunogenicity of influenza vaccines based on its  proprietary virosome technology platform in pre-clinical settings, with Sanofi Pasteur, the vaccines division of French pharma major Sanofi (Euronext: SAN).

If this project is successful it could result in a further and more extensive collaboration between the two companies.

"We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry," said Ronald Kempers, chief executive of Mymetics, adding: "We look forward to show that our proprietary virosome technology and more than 30 years of virosome vaccines expertise can make a valuable difference in improving the effectiveness and cost competitiveness of influenza vaccines."